US WorldMeds, LLC
4010 Dupont Circle, Suite 700
15 articles with US WorldMeds, LLC
In a 99 to 1 vote, the Senate passed the bill that looks to cut down on the flow of illegal narcotics entering the United States through the mail, as well as taking aim at the abuse of prescription opioid medication – a problem that has grown to an epidemic in the United States.
US WorldMeds And Salix Pharmaceuticals To Highlight Clinical Data For Opioid Withdrawal Treatment LUCEMYRA™ (lofexidine) At 2018 PAINWeek Conference
Product Theater, Three Posters and Oral Poster Presentation to be Featured
First and only FDA-approved, non-opioid medication indicated for mitigation of opioid withdrawal symptoms is now available for prescription
Camargo Congratulates US WorldMeds on Obtaining FDA Approval for the First Non-Opioid Medicine for the Management of Opioid Withdrawal Symptoms
Camargo Pharmaceutical Services, LLC congratulates US WorldMeds, LLC, on obtaining US Food and Drug Administration (FDA) approval for LUCEMYRA™ (lofexidine) tablets
U.S. Food and Drug Administration approved a new treatment to help patients manage withdrawal symptoms from opioid addiction.
FDA Advisory Committee Votes in Favor of LUCEMYRA™ (lofexidine) for the Mitigation of Opioid Withdrawal Symptoms
US WorldMeds announced that the US Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee voted 11 to 1 to recommend approval of lofexidine for mitigating opioid withdrawal symptoms.
US WorldMeds, LLC Release: New Clinical Trial To Study The Use Of MYOBLOC® Injections Into The Salivary Glands To Treat Sialorrhea (Drooling)
US WorldMeds, LLC Release: New Clinical Trial Investigates APOKYN for Treating Debilitating Morning Akinesia in Parkinson’s Disease Patients
US WorldMeds, LLC Completes Phase III Trial of Lofexidine for Treatment of Opiate Withdrawal Symptoms
US WorldMeds, LLC Completes Development of Instantaneous Reconstitution Dantrolene Sodium for Injection Product